

**Listing of Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-64. (Cancelled).

<sup>1</sup>  
~~65~~. (Previously presented) An isolated botulinum toxin type A comprising an amino acid sequence of which all or part of a leucine based motif of SEQ ID NO: 2 is deleted, wherein the deletion decreases a half-life of the botulinum toxin type A.

<sup>2</sup>  
~~66~~. (Previously presented) The botulinum toxin type A of claim <sup>1</sup>~~65~~ wherein the leucine based motif is SEQ ID NO: 7.

<sup>3</sup>  
~~67~~. (Previously presented) The botulinum toxin type A of claim <sup>1</sup>~~65~~ wherein the toxin is recombinantly produced.

68-71. (Canceled)

<sup>4</sup>  
~~72~~. (Currently amended) An isolated botulinum toxin type A comprising an amino acid sequence having a leucine based motif of SEQ ID NO: 2 in addition to a naturally-occurring leucine based motif of the toxin, wherein the ~~addition~~ additional leucine based motif of SEQ ID NO: 2 increases a the half-life of the botulinum toxin type A.

<sup>5</sup>  
~~73~~. (Previously presented) The botulinum toxin type A of claim <sup>4</sup>~~72~~ wherein the leucine based motif added to the botulinum toxin type A is selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 10 and SEQ ID NO: 12.

<sup>6</sup>  
~~74~~. (Previously presented) The botulinum toxin type A of claim <sup>4</sup>~~72~~ wherein the toxin is recombinantly produced.

DOCKET NO.: ALLE0014-100 (17355)

PATENT

75-77. (Canceled)

<sup>7</sup>  
78. (Currently amended) The botulinum toxin type A of claims <sup>1 2 3</sup>~~65~~, ~~66~~ or ~~67~~ wherein  
all of the leucine based motif of SEQ ID NO: 2 is deleted. <sub>1 1 1</sub>